Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1

Background & Aims: Liver disease has been described in 10%–15% of patients with autoimmune polyglandular syndrome type 1 (APS-1). After the discovery of cytochrome P450 1A2 (CYP1A2) as a hepatocellular autoantigen in liver-kidney microsomal autoantibody (LKM)-positive patients with APS-1, the in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 1998-02, Vol.114 (2), p.324-328
Hauptverfasser: Clemente, Maria Grazia, Meloni, Antonella, Obermayer-Straub, Petra, Frau, Fulvia, Manns, Michael Peter, de Virgiliis, Stefano
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background & Aims: Liver disease has been described in 10%–15% of patients with autoimmune polyglandular syndrome type 1 (APS-1). After the discovery of cytochrome P450 1A2 (CYP1A2) as a hepatocellular autoantigen in liver-kidney microsomal autoantibody (LKM)-positive patients with APS-1, the investigation of antiliver antibodies was extended to 11 Sardinian patients with APS-1. Methods: Indirect immunofluorescence and Western blotting analysis were performed to study the antiliver antibodies. Results: Immunofluorescence revealed LKM antibodies in 3 patients with APS-1, 1 of whom died of fulminant hepatitis. Western blotting showed a liver microsomal protein band of approximately 51 kilodaltons in the LKM-positive sera of these 3 patients. Western blotting performed with recombinant cytochrome P450 enzymes allowed the identification of CYP2A6 as a specific target antigen. Conclusions: LKM antibodies in APS-1 sera are specifically directed against CYP1A2 or CYP2A6, but their diagnostic and prognostic significance for liver disease remain to be determined. GASTROENTEROLOGY 1998;114:324-328
ISSN:0016-5085
1528-0012
DOI:10.1016/S0016-5085(98)70484-6